Reviews Invega


No reviews yet.

Invega Drug Description
INVEGA娨
(paliperidone) Extended-Release Tablets

WARNING
INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA RELATED PSYCHOSIS

Elderly patients with dementia-related psychosis treated with antipsychotic
drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials
(modal duration of 10 weeks), largely in patients taking atypical antipsychotic
drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7
times the risk of death in placebo-treated patients. Over the course of a typical
10-week controlled trial, the rate of death in drug-treated patients was about
4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes
of death were varied, most of the deaths appeared to be either cardiovascular
(e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.
Observational studies suggest that, similar to atypical antipsychotic drugs,
treatment with conventional antipsychotic drugs may increase mortality. The
extent to which the findings of increased mortality in observational studies
may be attributed to the antipsychotic drug as opposed to some characteristic(s)
of the patients is not clear. INVEGA® (paliperidone) Extended-Release Tablets
is not approved for the treatment of patients with dementia-related psychosis.
[see WARNINGS AND PRECAUTIONS]

DRUG DESCRIPTION



What are the possible side effects of paliperidone (Invega)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using paliperidone and call your doctor at once if you have any of these serious side effects:

fever, stiff muscles, confusion, sweating, fast or uneven heartbeats;
urinating less than usual or not at all;
restless muscle movements in your eyes, tongue, jaw, or neck;
tremor (uncontrolled...
Read All Potential Side Effects for Invega »




Paliperidone, the active ingredient in INVEGA® Extended-Release Tablets,
is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives.
INVEGA® contains a racemic mixture of (+)- and (-)- paliperidone. The chemical
name is (±)-3-[2-[4-(6-fluoro-1,2benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4Hpyrido[1,2-a]pyrimidin-4-one.
Its molecular formula is C23H27FN4O3
and its molecular weight is 426.49. The structural formula is:








Paliperidone is sparingly soluble in 0.1N HCl and methylene chloride; practically
insoluble in water, 0.1N NaOH, and hexane; and slightly soluble in N,N-dimethylformamide.
INVEGA® (paliperidone) Extended-Release Tablets are available in 1.5 mg
(orange-brown), 3 mg (white), 6 mg (beige), and 9 mg (pink) strengths. INVEGA®
utilizes OROS® osmotic drug-release technology.
Inactive ingredients are carnauba wax, cellulose acetate, hydroxyethyl cellulose,
propylene glycol, polyethylene glycol, polyethylene oxides, povidone, sodium
chloride, stearic acid, butylated hydroxytoluene, hypromellose, titanium dioxide,
and iron oxides. The 3 mg tablets also contain lactose monohydrate and triacetin.
Delivery System Components and Performance
INVEGA® uses osmotic pressure to deliver paliperidone at a controlled rate.
The delivery system, which resembles a capsule-shaped tablet in appearance,
consists of an osmotically active trilayer core surrounded by a subcoat and
semipermeable membrane. The trilayer core is composed of two drug layers containing
the drug and excipients, and a push layer containing osmotically active components.
There are two precision laser-drilled orifices on the drug-layer dome of the
tablet. Each tablet strength has a different colored water-dispersible overcoat
and print markings. In an aqueous environment, such as the gastrointestinal
tract, the water-dispersible color overcoat erodes quickly. Water then enters
the tablet through the semipermeable membrane that controls the rate at which
water enters the tablet core, which, in turn, determines the rate of drug delivery.
The hydrophilic polymers of the core hydrate and swell, creating a gel containing
paliperidone that is then pushed out through the tablet orifices. The biologically
inert components of the tablet remain intact during gastrointestinal transit
and are eliminated in the stool as a tablet shell, along with insoluble core
components.
Last reviewed on RxList: 3/25/2010




Invega Drug Description
INVEGA娨
(paliperidone) Extended-Release Tablets

WARNING
INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA RELATED PSYCHOSIS

Elderly patients with dementia-related psychosis treated with antipsychotic
drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials
(modal duration of 10 weeks), largely in patients taking atypical antipsychotic
drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7
times the risk of death in placebo-treated patients. Over the course of a typical
10-week controlled trial, the rate of death in drug-treated patients was about
4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes
of death were varied, most of the deaths appeared to be either cardiovascular
(e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.
Observational studies suggest that, similar to atypical antipsychotic drugs,
treatment with conventional antipsychotic drugs may increase mortality. The
extent to which the findings of increased mortality in observational studies
may be attributed to the antipsychotic drug as opposed to some characteristic(s)
of the patients is not clear. INVEGA® (paliperidone) Extended-Release Tablets
is not approved for the treatment of patients with dementia-related psychosis.
[see WARNINGS AND PRECAUTIONS]

DRUG DESCRIPTION



What are the possible side effects of paliperidone (Invega)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using paliperidone and call your doctor at once if you have any of these serious side effects:

fever, stiff muscles, confusion, sweating, fast or uneven heartbeats;
urinating less than usual or not at all;
restless muscle movements in your eyes, tongue, jaw, or neck;
tremor (uncontrolled...
Read All Potential Side Effects for Invega »




Paliperidone, the active ingredient in INVEGA® Extended-Release Tablets,
is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives.
INVEGA® contains a racemic mixture of (+)- and (-)- paliperidone. The chemical
name is (±)-3-[2-[4-(6-fluoro-1,2benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4Hpyrido[1,2-a]pyrimidin-4-one.
Its molecular formula is C23H27FN4O3
and its molecular weight is 426.49. The structural formula is:








Paliperidone is sparingly soluble in 0.1N HCl and methylene chloride; practically
insoluble in water, 0.1N NaOH, and hexane; and slightly soluble in N,N-dimethylformamide.
INVEGA® (paliperidone) Extended-Release Tablets are available in 1.5 mg
(orange-brown), 3 mg (white), 6 mg (beige), and 9 mg (pink) strengths. INVEGA®
utilizes OROS® osmotic drug-release technology.
Inactive ingredients are carnauba wax, cellulose acetate, hydroxyethyl cellulose,
propylene glycol, polyethylene glycol, polyethylene oxides, povidone, sodium
chloride, stearic acid, butylated hydroxytoluene, hypromellose, titanium dioxide,
and iron oxides. The 3 mg tablets also contain lactose monohydrate and triacetin.
Delivery System Components and Performance
INVEGA® uses osmotic pressure to deliver paliperidone at a controlled rate.
The delivery system, which resembles a capsule-shaped tablet in appearance,
consists of an osmotically active trilayer core surrounded by a subcoat and
semipermeable membrane. The trilayer core is composed of two drug layers containing
the drug and excipients, and a push layer containing osmotically active components.
There are two precision laser-drilled orifices on the drug-layer dome of the
tablet. Each tablet strength has a different colored water-dispersible overcoat
and print markings. In an aqueous environment, such as the gastrointestinal
tract, the water-dispersible color overcoat erodes quickly. Water then enters
the tablet through the semipermeable membrane that controls the rate at which
water enters the tablet core, which, in turn, determines the rate of drug delivery.
The hydrophilic polymers of the core hydrate and swell, creating a gel containing
paliperidone that is then pushed out through the tablet orifices. The biologically
inert components of the tablet remain intact during gastrointestinal transit
and are eliminated in the stool as a tablet shell, along with insoluble core
components.
Last reviewed on RxList: 3/25/2010




Invega Drug Description
INVEGA娨
(paliperidone) Extended-Release Tablets

WARNING
INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA RELATED PSYCHOSIS

Elderly patients with dementia-related psychosis treated with antipsychotic
drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials
(modal duration of 10 weeks), largely in patients taking atypical antipsychotic
drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7
times the risk of death in placebo-treated patients. Over the course of a typical
10-week controlled trial, the rate of death in drug-treated patients was about
4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes
of death were varied, most of the deaths appeared to be either cardiovascular
(e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.
Observational studies suggest that, similar to atypical antipsychotic drugs,
treatment with conventional antipsychotic drugs may increase mortality. The
extent to which the findings of increased mortality in observational studies
may be attributed to the antipsychotic drug as opposed to some characteristic(s)
of the patients is not clear. INVEGA® (paliperidone) Extended-Release Tablets
is not approved for the treatment of patients with dementia-related psychosis.
[see WARNINGS AND PRECAUTIONS]

DRUG DESCRIPTION



What are the possible side effects of paliperidone (Invega)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using paliperidone and call your doctor at once if you have any of these serious side effects:

fever, stiff muscles, confusion, sweating, fast or uneven heartbeats;
urinating less than usual or not at all;
restless muscle movements in your eyes, tongue, jaw, or neck;
tremor (uncontrolled...
Read All Potential Side Effects for Invega »




Paliperidone, the active ingredient in INVEGA® Extended-Release Tablets,
is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives.
INVEGA® contains a racemic mixture of (+)- and (-)- paliperidone. The chemical
name is (±)-3-[2-[4-(6-fluoro-1,2benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4Hpyrido[1,2-a]pyrimidin-4-one.
Its molecular formula is C23H27FN4O3
and its molecular weight is 426.49. The structural formula is:








Paliperidone is sparingly soluble in 0.1N HCl and methylene chloride; practically
insoluble in water, 0.1N NaOH, and hexane; and slightly soluble in N,N-dimethylformamide.
INVEGA® (paliperidone) Extended-Release Tablets are available in 1.5 mg
(orange-brown), 3 mg (white), 6 mg (beige), and 9 mg (pink) strengths. INVEGA®
utilizes OROS® osmotic drug-release technology.
Inactive ingredients are carnauba wax, cellulose acetate, hydroxyethyl cellulose,
propylene glycol, polyethylene glycol, polyethylene oxides, povidone, sodium
chloride, stearic acid, butylated hydroxytoluene, hypromellose, titanium dioxide,
and iron oxides. The 3 mg tablets also contain lactose monohydrate and triacetin.
Delivery System Components and Performance
INVEGA® uses osmotic pressure to deliver paliperidone at a controlled rate.
The delivery system, which resembles a capsule-shaped tablet in appearance,
consists of an osmotically active trilayer core surrounded by a subcoat and
semipermeable membrane. The trilayer core is composed of two drug layers containing
the drug and excipients, and a push layer containing osmotically active components.
There are two precision laser-drilled orifices on the drug-layer dome of the
tablet. Each tablet strength has a different colored water-dispersible overcoat
and print markings. In an aqueous environment, such as the gastrointestinal
tract, the water-dispersible color overcoat erodes quickly. Water then enters
the tablet through the semipermeable membrane that controls the rate at which
water enters the tablet core, which, in turn, determines the rate of drug delivery.
The hydrophilic polymers of the core hydrate and swell, creating a gel containing
paliperidone that is then pushed out through the tablet orifices. The biologically
inert components of the tablet remain intact during gastrointestinal transit
and are eliminated in the stool as a tablet shell, along with insoluble core
components.
Last reviewed on RxList: 3/25/2010




Invega Drug Description
INVEGA娨
(paliperidone) Extended-Release Tablets

WARNING
INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA RELATED PSYCHOSIS

Elderly patients with dementia-related psychosis treated with antipsychotic
drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials
(modal duration of 10 weeks), largely in patients taking atypical antipsychotic
drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7
times the risk of death in placebo-treated patients. Over the course of a typical
10-week controlled trial, the rate of death in drug-treated patients was about
4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes
of death were varied, most of the deaths appeared to be either cardiovascular
(e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.
Observational studies suggest that, similar to atypical antipsychotic drugs,
treatment with conventional antipsychotic drugs may increase mortality. The
extent to which the findings of increased mortality in observational studies
may be attributed to the antipsychotic drug as opposed to some characteristic(s)
of the patients is not clear. INVEGA® (paliperidone) Extended-Release Tablets
is not approved for the treatment of patients with dementia-related psychosis.
[see WARNINGS AND PRECAUTIONS]

DRUG DESCRIPTION



What are the possible side effects of paliperidone (Invega)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using paliperidone and call your doctor at once if you have any of these serious side effects:

fever, stiff muscles, confusion, sweating, fast or uneven heartbeats;
urinating less than usual or not at all;
restless muscle movements in your eyes, tongue, jaw, or neck;
tremor (uncontrolled...
Read All Potential Side Effects for Invega »




Paliperidone, the active ingredient in INVEGA® Extended-Release Tablets,
is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives.
INVEGA® contains a racemic mixture of (+)- and (-)- paliperidone. The chemical
name is (±)-3-[2-[4-(6-fluoro-1,2benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4Hpyrido[1,2-a]pyrimidin-4-one.
Its molecular formula is C23H27FN4O3
and its molecular weight is 426.49. The structural formula is:








Paliperidone is sparingly soluble in 0.1N HCl and methylene chloride; practically
insoluble in water, 0.1N NaOH, and hexane; and slightly soluble in N,N-dimethylformamide.
INVEGA® (paliperidone) Extended-Release Tablets are available in 1.5 mg
(orange-brown), 3 mg (white), 6 mg (beige), and 9 mg (pink) strengths. INVEGA®
utilizes OROS® osmotic drug-release technology.
Inactive ingredients are carnauba wax, cellulose acetate, hydroxyethyl cellulose,
propylene glycol, polyethylene glycol, polyethylene oxides, povidone, sodium
chloride, stearic acid, butylated hydroxytoluene, hypromellose, titanium dioxide,
and iron oxides. The 3 mg tablets also contain lactose monohydrate and triacetin.
Delivery System Components and Performance
INVEGA® uses osmotic pressure to deliver paliperidone at a controlled rate.
The delivery system, which resembles a capsule-shaped tablet in appearance,
consists of an osmotically active trilayer core surrounded by a subcoat and
semipermeable membrane. The trilayer core is composed of two drug layers containing
the drug and excipients, and a push layer containing osmotically active components.
There are two precision laser-drilled orifices on the drug-layer dome of the
tablet. Each tablet strength has a different colored water-dispersible overcoat
and print markings. In an aqueous environment, such as the gastrointestinal
tract, the water-dispersible color overcoat erodes quickly. Water then enters
the tablet through the semipermeable membrane that controls the rate at which
water enters the tablet core, which, in turn, determines the rate of drug delivery.
The hydrophilic polymers of the core hydrate and swell, creating a gel containing
paliperidone that is then pushed out through the tablet orifices. The biologically
inert components of the tablet remain intact during gastrointestinal transit
and are eliminated in the stool as a tablet shell, along with insoluble core
components.
Last reviewed on RxList: 3/25/2010




Invega Drug Description
INVEGA娨
(paliperidone) Extended-Release Tablets

WARNING
INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA RELATED PSYCHOSIS

Elderly patients with dementia-related psychosis treated with antipsychotic
drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials
(modal duration of 10 weeks), largely in patients taking atypical antipsychotic
drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7
times the risk of death in placebo-treated patients. Over the course of a typical
10-week controlled trial, the rate of death in drug-treated patients was about
4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes
of death were varied, most of the deaths appeared to be either cardiovascular
(e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.
Observational studies suggest that, similar to atypical antipsychotic drugs,
treatment with conventional antipsychotic drugs may increase mortality. The
extent to which the findings of increased mortality in observational studies
may be attributed to the antipsychotic drug as opposed to some characteristic(s)
of the patients is not clear. INVEGA® (paliperidone) Extended-Release Tablets
is not approved for the treatment of patients with dementia-related psychosis.
[see WARNINGS AND PRECAUTIONS]

DRUG DESCRIPTION



What are the possible side effects of paliperidone (Invega)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using paliperidone and call your doctor at once if you have any of these serious side effects:

fever, stiff muscles, confusion, sweating, fast or uneven heartbeats;
urinating less than usual or not at all;
restless muscle movements in your eyes, tongue, jaw, or neck;
tremor (uncontrolled...
Read All Potential Side Effects for Invega »




Paliperidone, the active ingredient in INVEGA® Extended-Release Tablets,
is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives.
INVEGA® contains a racemic mixture of (+)- and (-)- paliperidone. The chemical
name is (±)-3-[2-[4-(6-fluoro-1,2benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4Hpyrido[1,2-a]pyrimidin-4-one.
Its molecular formula is C23H27FN4O3
and its molecular weight is 426.49. The structural formula is:








Paliperidone is sparingly soluble in 0.1N HCl and methylene chloride; practically
insoluble in water, 0.1N NaOH, and hexane; and slightly soluble in N,N-dimethylformamide.
INVEGA® (paliperidone) Extended-Release Tablets are available in 1.5 mg
(orange-brown), 3 mg (white), 6 mg (beige), and 9 mg (pink) strengths. INVEGA®
utilizes OROS® osmotic drug-release technology.
Inactive ingredients are carnauba wax, cellulose acetate, hydroxyethyl cellulose,
propylene glycol, polyethylene glycol, polyethylene oxides, povidone, sodium
chloride, stearic acid, butylated hydroxytoluene, hypromellose, titanium dioxide,
and iron oxides. The 3 mg tablets also contain lactose monohydrate and triacetin.
Delivery System Components and Performance
INVEGA® uses osmotic pressure to deliver paliperidone at a controlled rate.
The delivery system, which resembles a capsule-shaped tablet in appearance,
consists of an osmotically active trilayer core surrounded by a subcoat and
semipermeable membrane. The trilayer core is composed of two drug layers containing
the drug and excipients, and a push layer containing osmotically active components.
There are two precision laser-drilled orifices on the drug-layer dome of the
tablet. Each tablet strength has a different colored water-dispersible overcoat
and print markings. In an aqueous environment, such as the gastrointestinal
tract, the water-dispersible color overcoat erodes quickly. Water then enters
the tablet through the semipermeable membrane that controls the rate at which
water enters the tablet core, which, in turn, determines the rate of drug delivery.
The hydrophilic polymers of the core hydrate and swell, creating a gel containing
paliperidone that is then pushed out through the tablet orifices. The biologically
inert components of the tablet remain intact during gastrointestinal transit
and are eliminated in the stool as a tablet shell, along with insoluble core
components.
Last reviewed on RxList: 3/25/2010





Other reviews about Invega on wordpress

Buy Invega Online Order Cheap Invega Generic Purchase Discount Without Prescription
  by worlddnews
FOLLOW THIS LINK FOR ENTER TO TRUSTED & REPUTABLE ONLINE DRUGSTORE WHERE YOU CAN GET ALL QUALIFIED INFORMATION ABOUT Invega ONLINE     And fitness centers they are ve uncovered is […]


Loose Screws Mental Health News
  by Kass
NAMI is touting a new atypical… in the press release for Johnson & Johnson. Michael J. Fitzpatrick, executive director of NAMI lent a statement  in J&J’s pr about […]


Topline Findings from Comparative Analysis of INVEGA(TM) and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress
  by julien42
TITUSVILLE, N.J., Oct. 8 /PRNewswire/ -- Preliminary results from a clinical study comparing INVEGA(TM) (paliperidone) Extended-Release Tablets to quetiapine (marketed as Seroquel(R)) and placebo in […]


Pharma's "me-too" drugs face skeptical docs and health insurers
  by Kass
As patents expire on a variety of drugmakers' moneymakers, pharma companies have gone to great lengths to structurally reinvent the successful drugs then tout the benefits that differ […]


I think it was the Invega
  by nakemiin
I'm so heavy right now. My body moves like it's underwater; my fingers are tiny weights attached to my hands; my eyes are glassy and I can't even […]


Invega --- Risperdal's "patent extender" falters in Europe
  by giannakali
Invega has always held some interest for me as I was on Risperdal for about 14 years. Invega is a copycat drug made only so Janssen could have […]


Janssen-Cilag International N.V. Withdraws Its Application For An Extension Of Indication For Invega (paliperidone)
  by maciekmaciek5
The European Medicines Agency (EMEA) has been formally notified by Janssen-Cilag International N.V. of its decision to withdraw its application for an extension of […]


Links of the week
  by giannakali
Metabolic Effects Significantly Lower With INVEGA(R) Compared To Olanzapine -- This is NON NEWS we already know that Risperdal has less weight gain/metabolic problems than Zyprexa. This does […]


Got my book
  by tai0316
Alright I bought The Dissociative identity Disorder Sourcebook today so, I have some reading ahead of me. I've been feeling off-balance today because my therapist is out of the office […]


Tired with no clear reason why. Lack of one med or taking the other?
  by tai0316
I got about 3 hours of sleep. I didn't take my Seroquel and as I feared I couldn't sleep. I spent most of the night and the early […]



Other reviews about Invega on web:

Information on INVEGA (paliperidone) and Schizophrenia. Approved by the FDA for the treatment of schizophrenia. INVEGA (paliperidone) and Treatment of Schizophrenia


Paliperidone (sold as INVEGA, INVEGA Sustenna), also known as 9-hydroxyrisperidone, is an atypical antipsychotic developed by Janssen Pharmaceutica. Paliperidone - Wikipedia, the free encyclopedia


Accurate, FDA approved Invega information for healthcare professionals and patients - brought to you by Drugs.com. Invega Official FDA information, side effects and uses.


Invega (paliperidone) is an antipsychotic medication used to treat schizophrenia. Includes Invega side effects, interactions and indications. Invega (paliperidone) Information from Drugs.com


Learn about the prescription medication Invega (Paliperidone), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Invega (Paliperidone) Drug Information: Uses, Side Effects, Drug ...


Invega – generic name paliperidone – is an atypical antipsychotic approved for the treatment of schizophrenia and used off-label to combat acute mania in patients with ... Invega - Antipsychotic Medication - Quick Facts About Invega ...


Learn about INVEGA® (paliperidone) Extended-Release Tablets a medication for the treatment of schizophrenia. INVEGA® (paliperidone) - Treatment of Schizophrenia


Invega is an atypical antipsychotic agent used to treat schizophrenia or schizoaffective disorder. Side effects and interactions are available at drugstore.com; plus get home ... Invega - drugstore.com. Low prices, side effects, interactions.


Learn about Invega from the publishers of the Physicians Desk Reference. Find prescription drug information resources including interactions, side effects, symptoms, treatment, and ... Invega | Prescription Drug Information, Side Effects | PDRHealth


Users' perspectives of Invega (paliperidone): inculding approved and off-label uses, pros and cons, side effects, and stuff your doctor doesn't tell you. Invega's Uses - The Good, The Bad and The Funny. From People Who ...





Featured Reviews

Reviews Levonorgestrel Tablet

Plan B One-Step Drug Description Plan B One-Step (levonorgestrel) Tablet, 1.5 mg, for Oral Use DRUG DESCRIPTION The Plan B One-Step tablet contains 1.5 mg of a single active steroid ingredient, levonorgestrel [18,19-Dinorpregn-4-en-20-yn-3-one-13-e...
Read More  |  Review This
Reviews Cefdinir

Omnicef Drug Description OMNICEF® (cefdinir) Capsules OMNICEF® (cefdinir) for Oral Suspension To reduce the development of drug-resistant bacteria and maintain the effectiveness of OMNICEF and other antibacterial drugs, OMNICEF...
Read More  |  Review This
Reviews Amikacin

Amikin Drug Description Amikin (amikacin sulfate) DRUG DESCRIPTION What are the possible side effects of amikacin (Amikin, Amikin Pediatric)? If you experience any of the following serious side effects, stop taking amikacin...
Read More  |  Review This
Reviews Raplon

Raplon Drug Description DRUG DESCRIPTION RAPLONTM (rapacuronium bromide) for Injection THIS DRUG SHOULD BE ADMINISTERED BY ADEQUATELY TRAINED INDIVIDUALS FAMILIAR WITH ITS ACTIONS, CHARACTERISTICS AND HAZARDS. RAPLONTM (rapacuronium...
Read More  |  Review This
Reviews EryPed

EryPed Drug Description Eryped 200 (erythromycin ethylsuccinate) Suspension Eryped 400 (erythromycin ethylsuccinate) Suspension Eryped Drops (erythromycin ethylsuccinate) Suspension To reduce the development of drug-resistant...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....